Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet ...

Antiplatelet medications are widely used worldwide; however, their use can present challenges in patients who require invasive procedures with a high thromboembolic risk, such as neuroendovascular ...

Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet ...

The MarketWatch News Department was not involved in the creation of this content. WATERTOWN, Mass., April 6, 2026 /PRNewswire/ -- PlateletDiagnostics, LLC (PlateletDx.com) today announced the ...

Randomized trials of platelet function and genetic testing to guide antiplatelet decisions following PCI have produced notoriously mixed results: now, an updated consensus document aims to fill some ...

An experimental genetic test can gauge a person's risk of developing potentially deadly blood clots, researchers report. People who scored high on the test had more than double the rate of heart ...

Use of platelet reactivity testing in ACS patients coming off P2Y12 inhibitors who may be at risk for perioperative bleeding can safely shorten the waiting time before CABG, potentially cutting ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

ROME, ITALY — Monitoring platelet function and individualizing antiplatelet therapy did not improve outcomes for elderly ACS patients undergoing coronary stenting, results of the ANTARCTIC trial show ...

WATERTOWN, Mass., April 6, 2026 /PRNewswire/ -- PlateletDiagnostics, LLC (PlateletDx.com) today announced the development of a first-in-class platelet function assay that measures phosphorylation of ...